Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of February 2022, with a report date of February 24, 2022. The document serves as a transaction notification regarding insider trading activities by a Person Discharging Managerial Responsibilities (PDMR).
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It is strictly a regulatory disclosure of a specific securities transaction.
| Metric | Value |
|---|---|
| Transaction Type | Acquisition of American Depositary Shares (ADSs) |
| Instrument ISIN | US37733W1053 |
| Transaction Date | February 22, 2022 |
| Exchange | New York Stock Exchange (XNYS) |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details two separate acquisitions of GSK ADSs by Dr. H. Barron, Chief Scientific Officer and President, R&D, on February 22, 2022:
- Executive Supplemental Savings Plan: Acquisition of 1,097.774 ADSs at $42.6900 per share.
- 401(k) Plan: Acquisition of 197 ADSs at $42.6900 per share.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, contingencies, or discussion of unusual items. It is a standard compliance notification under Rule 13a-16 or 15d-16.
Key Facts for Investor Verification
- Verify the total number of ADSs held by Dr. H. Barron following these acquisitions to assess insider confidence.
- Confirm the transaction price of $42.6900 against the market price of GSK ADSs on February 22, 2022.
- Note that this filing does not reflect the company's Q4 2021 or full-year 2021 financial results, which would be found in a separate Form 20-F or earnings release.